Current status of immunotherapy and gene therapy for high-grade gliomas

Cancer Control

Volumn 20, Issue 1, 2013, Pages 43-48

  Marsh, James C ^a   Goldfarb, Justin ^b   Shafman, Timothy D ^c   Diaz, Aidnag Z ^d  

^a Century Oncology Translational Research Consortium   (United States)

^b Sonoran Hematology and Oncology   (United States)

^c 21ST CENTURY ONCOLOGY   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; CD133 ANTIGEN; DENDRITIC CELL VACCINE; GANCICLOVIR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NESTIN; TEMOZOLOMIDE; THYMIDINE KINASE; TUMOR ANTIGEN; VALACICLOVIR; VIRUS VECTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GENE THERAPY; CANCER GRADING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GLIOBLASTOMA; GLIOMA; HUMAN; HYPONATREMIA; INJECTION SITE REACTION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEURAL STEM CELL; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SIDE EFFECT; SUICIDE GENE THERAPY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WOUND COMPLICATION;

EID: 84871552831     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481302000107     Document Type: Review

References (56)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
3. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
4. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583-1588.
5. Bauman GS, Gaspar LE, Fisher BJ, et al. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1994;29(4):835-839.
6. Roa W, Xing JZ, Small C, et al. Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme. Expert Rev Anticancer Ther. 2009;9(11):1643-1650.
7. Ahluwalia MS. American Society of Clinical Oncology 2011 CNS tumors update. Expert Rev Anticancer Ther. 2011;11(10):1495-1497.
8. Brower V. Early-stage progress on glioma vaccines. J Natl Cancer Inst. 2011;103(18):1361-1362.
9. Wheeler CJ, Black KL. Vaccines for glioblastoma and high-grade glioma. Expert Rev Vaccines. 2011;10(6):875-886.
10. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-4729.
11. Komotar RJ, Starke RM, Connolly ES, Sisti MB. Epidermal growth factor receptor vaccination for glioblastoma multiforme. Neurosurgery. 2011; 68(2):N20-N21.
12. Lesniak MS. Immunotherapy for glioblastoma: the devil is in the details. J Clin Oncol. 2011;29(22):3105-3106.
13. Chamberlain MC. How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine. J Clin Oncol. 2011;29(17):e517-e520.
14. Chang CN, Huang YC, Yang DM, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci. 2011;18(8):1048-1054.
15. Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother. 2011;34(4):382-389.
16. Jie X, Hua L, Jiang W, et al. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys. 2012;62(1):91-99.
17. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
18. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005;353(8):811-822.
19. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene. 2004;23(43):7267-7273.
20. Altaner C. Glioblastoma and stem cells. Neoplasma. 2008;55(5):369-374.
21. Fukaya R, Ohta S, Yamaguchi M, et al. Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Lett. 2010;291(2):150-157.
22. Singh S, Dirks PB. Brain tumor stem cells: identification and concepts. Neurosurg Clin N Am. 2007;18(1):31-38.
23. Pérez Castillo A, Aguilar-Morante D, Morales-García JA, Dorado J. Cancer stem cells and brain tumors. Clin Transl Oncol. 2008;10(5):262-267.
24. Mao XG, Zhang X, Zhen HN. Progress on potential strategies to target brain tumor stem cells. Cell Mol Neurobiol. 2009;29(2):141-155.
25. Xiao ZY, Tang H, Xu ZM, et al. An experimental study of dendritic cells transfected with cancer stem-like cells RNA against 9L brain tumors. Cancer Biol Ther. 2011;11(11):974-980.
26. Pellegatta S, Finocchiaro G. Dendritic cell vaccines for cancer stem cells. Methods Mol Biol. 2009;568:233-247.
27. Xu Q, Liu G, Yuan X, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells. 2009;27(8):1734-1740.
28. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-5525.
29. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973-4979.
30. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50(7):337-344.
31. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11(11):4160-4167.
32. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14(10):3098-3104.
33. Muragaki Y, Maruyama T, Iseki H, et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma: clinical article. J Neurosurg. 2011;115(2):248-255.
34. Liu SQ, Saijo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat Med. 1995;1(3):267-271.
35. Liu SQ, Shiraiwa H, Kawai K, et al. Tumor-specific autologous cytotoxic T lymphocytes from tissue sections. Nat Med. 1996;2(12):1283.
36. Ohno T. Autologous cancer vaccine: a novel formulation. Microbiol Immunol. 2003;47(4):255-263.
37. Ohno T. Autologous formalin-fixed tumor vaccine. Curr Pharm Des. 2005;11(9):1181-1188.
38. Sakamoto N, Ishikawa E, Yamamoto T, et al. Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma: three case reports. Neurol Med Chir (Tokyo). 2011;51(4):319-325.
39. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256(5063):1550-1552.
40. Chiocca EA, Aguilar LK, Bell SD, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol. 2011;29(27):3611-3619.
41. Ayala G, Satoh T, Li R, et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006;13 (4):716-728.
42. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther. 2000;1(2):195-203.
43. Immonen A, Vapalahti M, Tyynelä K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther. 2004;10(5):967-972.
44. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther. 2000;11(16):2197-2205.
45. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A. 2000;97(26):14720-14725.
46. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992;255(5052):1707-1710.
47. Nunes MC, Roy NS, Keyoung HM, et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med. 2003;9(4):439-447.
48. Doetsch F, García-Verdugo JM, Alvarez-Buylla A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci. 1997;17(13):5046-5061.
49. Levison SW, Goldman JE. Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat forebrain. Neuron. 1993;10(2):201-212.
50. Luskin MB. Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone. Neuron. 1993;11(1):173-189.
51. Gould E, Beylin A, Tanapat P, et al. Learning enhances adult neurogenesis in the hippocampal formation. Nat Neurosci. 1999;2(3):260-265.
52. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA. 2000;97(23):12846-12851.
53. Kim SU. Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev. 2011;7(1):130-140.
54. Najbauer J, Danks MK, Kim SU, et al. Neural stem cell mediated tumor-selective gene therapy: towards high grade glioma clinical trials. Mol Ther. 2008;16(suppl 1):S136.
55. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62(13):3603-3608.
56. Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol. 2012;2:169. Epub 2012 November 26.